Visual deficit possibly caused by lutetium-177 PSMA treatment
Sign Up to like & getrecommendations! Published in 2018 at "BMJ Case Reports"
DOI: 10.1136/bcr-2018-225508
Abstract: This report describes a case of a 54-year-old man who underwent lutetium-177-PSMA therapy in the setting of metastatic castration-resistant prostate cancer (mCRPC) in the University Medical Center Utrecht. Following administration of the second cycle, patient… read more here.
Keywords: deficit possibly; 177 psma; lutetium 177; psma ... See more keywords